Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | USP9X | Q93008 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CLK2 | P49760 | 2/20 | 0.32 |
| ▸ | CLK3 | P49761 | 2/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13154023 | 0.82 | HCAR2 (0.60) | HCAR2ALDH1A1SMN1; SMN2KDM4EHPGD | |
| SCHEMBL17773175 | 0.80 | ALDH1A1 (0.51) | HCAR2ALDH1A1SMN1; SMN2KDM4EHPGD | |
| SCHEMBL27858708 | 0.79 | HCAR2 (0.72) | HCAR2ALDH1A1SMN1; SMN2GAARAB9A | |
| SCHEMBL23224219 | 0.78 | SMN1; SMN2 (0.50) | HCAR2ALDH1A1SMN1; SMN2KDM4EHPGD | |
| SCHEMBL4781387 | 0.77 | — | — | |
| SCHEMBL186167 | 0.77 | — | — | |
| SCHEMBL2552716 | 0.76 | HCAR2 (0.56) | HCAR2ALDH1A1CDC7DBF4 | |
| SCHEMBL328096 | 0.75 | — | — | |
| SCHEMBL1435803 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL9653796 | 0.75 | HCAR2 (0.96) | HCAR2ALDH1A1SMN1; SMN2KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731967-B2 | Inhibitors of TRIM33 and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11466013-B2 | ERK inhibitor and use thereof | BETTA PHARMACEUTICALS CO., LTD (CN) | 2022-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731967-B2 | Inhibitors of TRIM33 and methods of use | TRIM33, TRIM28, TRIM4 | HCAR2 4029/4885ALDH1A1 3246/4885SMN1; SMN2 639/4885 |
| US-11466013-B2 | ERK inhibitor and use thereof | MAPK1, MAPK4, MAPK7 | HCAR2 3981/4885ALDH1A1 1793/4885SMN1; SMN2 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.